In a recent interview with InvestorNews host Tracy Hughes, Larry Braga, President and CEO of AscentX Medical, described gastroesophageal reflux disease (GERD) as one of the most common gastrointestinal conditions globally, affecting a significant portion of the population and largely managed today through pharmaceutical intervention.Braga noted that while proton pump inhibitors (PPIs) dominate the treatment landscape and provide symptom relief for many patients, a meaningful subset experiences what is known as “breakthrough,” where medications no longer adequately control reflux. It is this group that AscentX Medical is targeting with its regenerative biomaterial platform.The company’s approach centers on a minimally invasive, endoscopically delivered injection of proprietary collagen and microspheres into the lower esophageal sphincter. The material is designed to stimulate the body’s own healing response, promoting collagen formation that reinforces the weakened barrier between the stomach and esophagus. According to Braga, the objective is not short-term symptom management, but a longer-term correction that could extend for years.The procedure itself is expected to take approximately one hour and is positioned as a middle-ground solution between chronic medication use and invasive surgical intervention. Braga emphasized that the platform builds on more than three decades of research in regenerative biomaterials, originally developed for aesthetic applications such as wrinkle and acne scar treatment, and now being extended into therapeutic indications.Beyond GERD, AscentX Medical is advancing additional pipeline applications, including stress urinary incontinence (SUI) and fecal incontinence, both of which leverage the same underlying principle of tissue bulking and regeneration to restore function. These programs remain in earlier stages of development but reflect a broader strategy to apply the platform across multiple high-need conditions.Near-term milestones include the completion of preclinical studies and the initiation of a small pilot clinical trial, expected to generate the data required to support expanded trials and future regulatory submissions.

In a recent interview with InvestorNews host Tracy Hughes, Dr. Iqbal Sandhu, Chairman of the Scientific Advisory Board at AscentX Medical, outlined the scale and clinical burden of gastroesophageal reflux disease (GERD), a condition affecting tens of millions of patients and defined by the backward flow of stomach acid into the esophagus due to a compromised lower esophageal sphincter.Dr. Sandhu described GERD’s hallmark symptom—persistent heartburn—as more than a nuisance, noting its broader impact on quality of life, from disrupted sleep to dietary restriction and social anxiety. Patients often rely on proton pump inhibitors (PPIs), which suppress stomach acid but require long-term adherence and raise concerns about side effects. Surgical interventions exist but are invasive and frequently avoided by patients, leaving what he characterized as a significant treatment gap.That gap is where AscentX Medical is positioning its regenerative injectable biomaterial platform, known as G125. The approach centers on delivering a biocompatible material into the gastroesophageal junction, where it acts as a scaffold for the body’s own tissue regeneration. Over time, the material integrates with surrounding structures, promoting collagen deposition and vascularization to form a functional barrier that supports the weakened sphincter.“It’s not viewed as foreign by the body,” Dr. Sandhu explained, emphasizing that stability, non-migration, and the absence of inflammatory response are critical design features. The objective is not to reconstruct anatomy surgically, but to augment the natural barrier function in a minimally invasive, office-based procedure.The company has completed the design and patenting of a specialized delivery needle intended to precisely place the biomaterial within the submucosal layer. Preclinical animal studies are the next step, with evaluations planned at 30-day and six-month intervals to assess positioning, durability, and tissue response. Positive outcomes would support progression into clinical trials and regulatory pathways.For Dr. Sandhu, an interventional gastroenterologist, the appeal lies in scalability. Unlike more complex endoscopic or surgical procedures, the injection-based approach could be readily adopted across standard gastroenterology practices, potentially expanding access to a middle-ground therapy between medication and surgery.

In a recent Critical Minerals Institute (CMI) Masterclass, “The Critical Mineral that Literally Defines Time – Cesium,” the discussion began with a simple but underappreciated fact: the modern world keeps time using a metal most investors have never heard of.Hosted by Jack Lifton, Co-Chair of the Critical Minerals Institute and one of the foremost authorities on critical minerals, the session positioned cesium not as a niche specialty element, but as foundational infrastructure. The international definition of the second—9,192,631,770 oscillations of the cesium-133 atom—anchors GPS systems, telecommunications networks, financial markets, and military navigation.Without it, modern synchronization collapses.Against that backdrop, Robin Dunbar, President, CEO, and Director of Grid Metals Corp. (TSXV: GRDM | OTCQB: MSMGF), outlined what may be one of the most consequential cesium developments in recent years. Alongside Brandon Smith and industry advisor Austin Devaney, the conversation traced the company’s evolution from lithium exploration in southeastern Manitoba to the identification of a pollucite-rich system—one of the only minerals from which cesium can be economically extracted.The geology is unusually favorable. The Lucy South pegmatite lies close to surface, flat-lying, and laterally continuous—more akin to a quarry than a conventional underground mining operation. Most intercepts occur within 30 metres, materially reducing both technical complexity and capital requirements.That matters because cesium is not just rare—it is structurally scarce.Globally, only a handful of deposits have ever been identified, and fewer still have reached production. Supply remains concentrated, processing capacity limited, and new discoveries exceptionally uncommon. As Lifton noted during the session, even historically significant deposits have often been overlooked until acquired by more strategically minded actors.From a market perspective, cesium presents a paradox. It is both invisible and indispensable. Its best-known use—cesium formate drilling fluids—operates on a closed-loop rental system, where material is recovered and reused due to its scarcity. Beyond that, cesium enables atomic clocks, aerospace systems, infrared technologies, catalysis, medical imaging, and advanced electronics. In many of these applications, substitution is either impractical or impossible.Austin Devaney, drawing on his experience at Albemarle Corporation (NYSE: ALB), described a market defined by two dynamics: small volume, but high strategic value. It is not a bulk commodity story—it is a precision supply chain story.And that distinction is becoming increasingly important.As Western governments and industries move to secure critical mineral supply chains, materials like cesium are shifting from obscurity to strategic relevance. The Masterclass repeatedly returned to this point: control of supply, processing capability, and jurisdictional alignment now matter as much as discovery itself.For the Critical Minerals Institute, this is precisely the terrain it was built to address. As outlined in its latest release, CMI operates as a global think tank connecting capital markets, policymakers, and industry through Masterclasses, research, and its annual summit in Toronto.In that context, the Grid Metals discussion was less about a single project and more about a broader shift in how markets assign value to materials that sit deep within the technological stack.Because cesium does not trade like copper or lithium. It does not benefit from broad investor awareness or liquid pricing mechanisms. Its importance is revealed not in volume, but in consequence.And as Lifton framed it, that may ultimately be the defining characteristic of the next generation of critical minerals.The ones that matter most are often the least visible—until they are no longer available.